David has spent the past 20 years combining his disciplined approach to science with the business of effective drug development and corporate management.   David is the President and CEO of Arcellx, a company he founded in 2015.  Prior to Arcellx, he was a Director and CSO at Zyngenia, Inc., and led the company’s development of multi-specific antibody-based therapeutics.  From 2006 to 2009, David consulted with leading scientists, executives, and venture firms in assisting startup biotech companies with the many strategic and operational challenges associated with early stage drug development.  In 2004, he served as Vice President of Research at Cellective Therapeutics, a start-up antibody company acquired by MedImmune in October 2005.  David began his biotech career in 1996 at Human Genome Sciences (HGS) where he spent 8 years guiding the preclinical development of antibodies and genomics-based therapeutics.  Prior to joining HGS, David worked at the National Cancer Institute, NIH where he investigated neoplastic transformation of B lymphocytes. David received his B.S. from Haverford College and his Ph.D. from the University of Pennsylvania.

Angela has extensive experience in clinical development, medical affairs, and business development, having led clinical programs in oncology and cell & gene therapy in a variety of pharmaceutical settings. Angela previously served as Chief Medical Officer of NKarta Therapeutics and Arvinas.

At Novartis, Angela served as the first Global Clinical Program Head for CAR-T, and helped build the CART-19 (CTL019, Kymriah) program from the ground up. Prior to that, as Head of Clinical Evaluation for the Novartis Oncology Business Development group, she was extensively involved with licensing in new compounds to strengthen the Novartis oncology and hematology pipeline, including CTL019 (Kymriah) and SelG1 (Crizanlizumab). Earlier at Novartis, Angela was a Clinical Lead for the development of new oncology assets including panobinostat (Farydak) and PI3K inhibitors. At Exelixis, Angela served as Clinical Lead for multiple drugs in early development, including cobimetinib (Cotellic). At Johnson & Johnson, she held a medical affairs role supporting oncology products.

Angela completed her undergraduate studies at Rensselaer through the accelerated biomedical program, and went on to received her MD from Albany Medical College in New York, followed by surgical residency. She obtained her MBA from NYU Stern School of Business.

Prior to joining Arcellx, Han worked in the Corporate Development and Ventures group at AstraZeneca where he focused on mergers and acquisitions, transformative deals, strategic equity investments, and helped manage AstraZeneca/MedImmune’s equity portfolio of over 25 companies. Prior to AstraZeneca, Han was an integral part of two biotech start-ups that both had successful exits where his activities included conducting IND enabling animal studies, business development, and leading fundraising efforts. Han’s experience includes being on the board of multiple companies and over $6b in business development/equity deals. Han received his BA in Genetics and minor in Chemistry from the University of California, Berkeley. He received his PhD in Genetics and MBA from Yale University.

Shashi has over 25 years of experience in biological CMC development and manufacturing and is the company’s Vice President of Protein Sciences. Prior to joining Arcellx, he was head of Process Development at Jazz. Prior to Jazz he has held various CMC leadership positions at Alexion, Synageva, Zyngenia, Teva, Cogenesys and Human Genome Sciences. Shashi has extensive knowledge of all biological CMC functions with experience of developing a CMC strategy from early pre-clinical stage through commercialization. Shashi was a co-recipient of Technology award from government of India. Shashi has a Ph.D. in Biochemistry.

Ms. Fix is Senior Vice President, Regulatory Affairs with responsibility for regulatory strategy and interactions with regulatory agencies, including the U.S. Food and Drug Administration and the European Medicines Agency, which oversee the development and commercialization of Arcellx’ cell therapy product candidates. Prior to joining Arcellx in September 2019, Ms. Fix was Senior Vice President of Regulatory Affairs and was on the Senior Management team at Novavax, leading the development of multiple late stage vaccine development programs, including a Phase 3 global maternal immunization clinical trial being conducted in 11 countries, and two Phase 3 older adult programs for the RSV and influenza franchises.  Prior to joining Novavax in April 2013, she was Senior Director of Regulatory Affairs at Emergent Biosolutions after serving in Regulatory Affairs positions of increasing responsibility at a number of biotechnology/pharmaceutical companies, including Human Genome Sciences, Shire, MedImmune and Baxter. During Ms. Fix’s career, she has successfully conducted numerous global regulatory meetings, and has been responsible for multiple INDs, BLAs, NDAs, and post-marketing programs, has been a key member of business development/due diligence teams, has worked with the World Health Organization on global health initiatives, and has built successful Regulatory departments from the ground up.  Ms. Fix received her Bachelor of Science degree in Biology from the University of Illinois, her Master of Science degree in Molecular Biology from the University of Virginia’s Biotechnology program, and her Master of Business Administration degree in Management from Johns Hopkins University.

Travis Quigley oversees clinical development activities at Arcellx and is responsible for moving oncology programs to, and through the clinic. Travis brings close 20 years of oncology and clinical development experience to Arcellx. Most recently, he was VP of Early Oncology Development at bluebird bio, working with research and development to build a stable of oncology programs and collaborations. Travis was the Program and Clinical Leader for the bluebird anti-BCMA CAR-T program including the Celgene collaboration. Previously, Travis held roles of increasing responsibility at Foundation Medicine and Infinity Pharmaceuticals, working on clinical development trials demonstrating the utility of  a pan-cancer genomic sequencing assay and small molecule clinical trials, respectively. Before moving to industry, Travis was at Dana Farber Cancer Institute in Boston working with Industry collaborators on the early development of an array of Phase 1 programs including  the development of Gleevec® and Sutent® for Gastrointestinal Stromal Tumors, and Yondelis® in Soft Tissue Sarcomas, leading to their approval. Travis earned his BS from Villanova University, where he was a Division 1 swimmer and conference champion,  and his MS from University of Massachusetts.

David has over 20 years of biopharmaceutical research and drug development experience in oncology. Prior to joining Arcellx, he spent 18 years at MedImmune, the global biologics research and development unit of AstraZeneca, where he held roles of increasing responsibility.  While serving as the head of the antibody drug conjugate strategic area at AstraZeneca, he managed a portfolio of over 20 pipeline projects spanning discovery to phase I. Throughout his tenure at AstraZeneca, David had led the target discovery and validation group as well as several preclinical/clinical phase programs employing various therapeutic approaches including monoclonal antibodies, immunoconjugates, peptide mimetics, RNAi and cellular therapies targeting various molecules important in the development of cancer. Prior to this experience, David worked at Genentech where he focused on genomics-based target discovery and monoclonal antibody targeting in cancer. He received his B.S. in biology from Virginia Tech before receiving his PhD from the University of Virginia.